​

Zentalis Pharmaceuticals (ZNTL) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Zentalis Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$67.42M

0

Main Segment (Y)

Reportable Segment

Zentalis Pharmaceuticals Revenue by Period

Zentalis Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$67.42M100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--100.00%
2018-12-31$14.00K-

Zentalis Pharmaceuticals generated $67.42M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Zentalis Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30--100.00%
2024-03-31$40.56M1827.76%
2023-12-31$2.10M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--

Zentalis Pharmaceuticals generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Zentalis Pharmaceuticals Revenue Breakdown

Zentalis Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Reportable Segment$67.42M

Zentalis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable Segment (100.00%).

Zentalis Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BPMCBlueprint Medicines$508.82M$128.18M
DAWNDay One Biopharmaceuticals$131.16M$20.07M
GLUEMonte Rosa Therapeutics$75.62M$4.70M
ZNTLZentalis Pharmaceuticals$67.42M-
KYMRKymera Therapeutics$47.07M$3.74M
ITOSiTeos Therapeutics$35.00M$35.00M
SNDXSyndax Pharmaceuticals$23.68M$12.50M
DSGNDesign Therapeutics--
CGEMCullinan Oncology--
PTGXProtagonist Therapeutics-$4.67M
RVMDRevolution Medicines--
ANNXAnnexon--
SANASana Bio--
INZYInozyme Pharma--
OLMAOlema Pharmaceuticals--
ERASErasca--

ZNTL Revenue FAQ

What is Zentalis Pharmaceuticals’s yearly revenue?

Zentalis Pharmaceuticals's yearly revenue for 2024 was $67.42M, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. ZNTL's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Zentalis Pharmaceuticals’s quarterly revenue?

Zentalis Pharmaceuticals's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $40.56M, a 1827.76% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). ZNTL's quarterly revenue for Q4 2023 was $2.1M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).

What is Zentalis Pharmaceuticals’s revenue growth rate?

Zentalis Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are Zentalis Pharmaceuticals’s revenue streams?

Zentalis Pharmaceuticals's revenue streams in c 24 are Reportable Segment

What is Zentalis Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Zentalis Pharmaceuticals was Reportable Segment. This segment made a revenue of $67.42M, representing 100.00% of the company's total revenue.